Sally F. Barrington

King's College London & Guy's And St Thomas' PET Centre
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 138 publications

A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer.

A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 10, 2026

A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.

A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 10, 2026

The 68Ga-siderophore approach to infection imaging: evaluation of [68Ga]Ga-DFO in patients with vascular graft infection.

The 68Ga-siderophore approach to infection imaging: evaluation of [68Ga]Ga-DFO in patients with vascular graft infection.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 27, 2025

AI Improves Agreement and Reduces Time for Quantifying Metabolic Tumour Burden in Hodgkin Lymphoma.

AI Improves Agreement and Reduces Time for Quantifying Metabolic Tumour Burden in Hodgkin Lymphoma.

Journal: Hematology reports

Published: September 04, 2025

Automated RECOMIA AI-based total metabolic tumor volume in lymphoma - a retrospective study.

Automated RECOMIA AI-based total metabolic tumor volume in lymphoma - a retrospective study.

Journal: EJNMMI research

Published: August 14, 2025

Improving the predictive value of end-of-treatment PET/ CT in diffuse large B-cell lymphoma.

Improving the predictive value of end-of-treatment PET/ CT in diffuse large B-cell lymphoma.

Journal: Haematologica

Published: July 31, 2025

Predicting 2-year time to progression in diffuse large B cell lymphoma using 3D CNNs on whole-body PET/CT scans.

Predicting 2-year time to progression in diffuse large B cell lymphoma using 3D CNNs on whole-body PET/CT scans.

Journal: EJNMMI research

Published: July 21, 2025

Working towards harmonization of clinical trial reporting in Hodgkin lymphoma.

Working towards harmonization of clinical trial reporting in Hodgkin lymphoma.

Journal: HemaSphere

Published: July 04, 2025

Inter-reader agreement of quantitative FDG PET/CT biomarkers in lymphoma: a multicentre evaluation of MTV, TLG and Dmax.

Inter-reader agreement of quantitative FDG PET/CT biomarkers in lymphoma: a multicentre evaluation of MTV, TLG and Dmax.

Journal: BMC medical imaging

Published: June 19, 2025

MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.

MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy.

Journal: British journal of haematology

Published: April 10, 2025

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials.

Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials.

Journal: Blood cancer journal

Published: February 17, 2025

Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.

Management of relapsed or refractory large B-cell lymphoma: A British Society for Haematology Guideline.

Journal: British journal of haematology

Published: February 07, 2025

Showing 1-12 of 138

Last Updated: 09/26/2026